Chemotherapy News and Research

Latest Chemotherapy News and Research

Johns Hopkins receives $1.9M NIH grant to establish new center for sleep research

More than one-quarter of the adult population of the U.S. suffers from sleep disturbances known to contribute to life-threatening illnesses such as cardiovascular disease, diabetes, and dementia as well as depression, chronic pain, and fatigue. Often such sleeplessness is a consequence of obesity, lifestyle, and work.

27 Nov 2012

Paper illuminates importance of PKM2 in cancer development and progression

Researchers at The University of Texas MD Anderson Cancer Center have tracked down a cancer-promoting protein's pathway into the cell nucleus and discovered how, once there, it fires up a glucose metabolism pathway on which brain tumors thrive.

26 Nov 2012

Nonfunctional MED12 gene linked to chemotherapy resistance

Research published in Cell shows that people with tumors that have a nonfunctional version of the mediator 12 gene are resistant to drugs used to treat lung and colon cancer such as gefitinib.

26 Nov 2012

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Seattle Genetics, Inc. announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides (MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL).

26 Nov 2012

Avermectin family of drugs shows promise against TB

A well-established family of drugs used to treat parasitic diseases is showing surprising potential as a therapy for tuberculosis (TB), according to new research from University of British Columbia microbiologists.

26 Nov 2012

BSD-2000 Hyperthermia System purchased by Cancer Treatment Centers of America

BSD Medical Corporation, a leading provider of medical systems that utilize targeted heat therapy to treat cancer, announced today that the Cancer Treatment Centers of America (CTCA) at Western Regional Medical Center (WRMC), located in Goodyear, Arizona, has purchased a BSD-2000 Hyperthermia System (BSD-2000).

26 Nov 2012

Bowel cancer and GIST patients could benefit from novel oral drug

Two phase 3 trials, published in The Lancet, have shown that a novel oral drug called regorafenib could offer survival benefits to people with bowel (colorectal) cancer or gastrointestinal stromal tumour (GIST) following failure of existing treatments.

22 Nov 2012

TGF-betaR inhibitors may counter drug resistance in cancer patients with MED12 mutations

Cancer therapies often have short-lived benefits due to the emergence of genetic mutations that cause drug resistance. A key gene that determines resistance to a range of cancer drugs has been reported in a study published by Cell Press November 21st in the journal Cell.

22 Nov 2012

Homing beacon drugs can kill cancer cells

A medical researcher with the University of Alberta and his team just published their findings about their work on developing 'homing beacon drugs' that kill only cancer cells, not healthy ones, thanks to nano-technology.

22 Nov 2012

Regorafenib able to control resistant gastrointestinal stromal tumor

A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial.

21 Nov 2012

UNSW-developed nanoparticle could improve effectiveness of chemotherapy for neuroblastoma

In a world-first, researchers from the Australian Centre for Nanomedicine at the University of New South Wales (UNSW) in Sydney have developed a nanoparticle that could improve the effectiveness of chemotherapy for neuroblastoma by a factor of five.

21 Nov 2012

Gabrielle's Angel Foundation announces recipients of new collaborative grants for cancer research

Gabrielle's Angel Foundation for Cancer Research today announced grant recipients of its first-ever Collaborative Research grant program. The inaugural awards total $800,000 for two groundbreaking research initiatives that span the medical capitals of New York, Boston and Chicago.

21 Nov 2012

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced that its selective histone deacetylase (HDAC) inhibitors will be featured in five posters and one oral presentation at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place December 8-11, 2012, in Atlanta, Georgia.

21 Nov 2012

Certain mutated cells continue DNA replication process even after drug treatment

Certain mutated cells keep trying to replicate their DNA - with disastrous results - even after medications rob them of the raw materials to do so, according to new research from USC.

21 Nov 2012

Concord Medical third quarter 2012 total net revenues increase 65.2% to RMB206.1 million

Concord Medical Services Holdings Limited, a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China and the parent of Chang'an Hospital, today reported its unaudited consolidated financial results for the third quarter ended September 30, 2012.

21 Nov 2012

USPTO issues Notice of Allowance to Sanovas’ nested balloon catheter

Sanovas, Inc., a life science technology company focused on developing and commercializing the next-generation of micro-invasive diagnostics, devices and drug delivery technologies, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company's nested balloon catheter for localized drug delivery, a component of Sanovas' Vas Zeppelin Smart Catheter technology portfolio.

20 Nov 2012

Diffusion Pharmaceuticals completes trans sodium crocetinate Phase I trial on glioblastoma

Diffusion Pharmaceuticals LLC, a biotechnology company developing innovative cancer treatments, today announced that it has successfully completed a Phase I clinical trial of its lead compound trans sodium crocetinate (TSC) in nine patients with newly diagnosed primary brain cancer (glioblastoma or GBM).

19 Nov 2012

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

19 Nov 2012

Bevacizumab ruled out for stage III colorectal cancer

Findings from the AVANT trial do not support the use of bevacizumab in patients receiving oxaliplatin-based chemotherapy for resected stage III or high-risk stage II colon carcinoma.

19 Nov 2012

Biomolecular imaging: an interview with Professor Roger Reddel

The reason Children’s Medical Research Institute (CMRI) exists is to find ways to treat or prevent childhood disease. Our research programs are focussed on the areas of cancer cell growth, nerve cell signalling, embryology and gene therapy. These four programs have a shared aim of translating novel findings into new treatments for the benefit of families everywhere.

19 Nov 2012

Chemotherapy News and Research

Latest Chemotherapy News and Research

Johns Hopkins receives $1.9M NIH grant to establish new center for sleep research

Paper illuminates importance of PKM2 in cancer development and progression

Nonfunctional MED12 gene linked to chemotherapy resistance

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Avermectin family of drugs shows promise against TB

BSD-2000 Hyperthermia System purchased by Cancer Treatment Centers of America

Bowel cancer and GIST patients could benefit from novel oral drug

TGF-betaR inhibitors may counter drug resistance in cancer patients with MED12 mutations

Homing beacon drugs can kill cancer cells

Regorafenib able to control resistant gastrointestinal stromal tumor

UNSW-developed nanoparticle could improve effectiveness of chemotherapy for neuroblastoma

Gabrielle's Angel Foundation announces recipients of new collaborative grants for cancer research

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

Certain mutated cells continue DNA replication process even after drug treatment

Concord Medical third quarter 2012 total net revenues increase 65.2% to RMB206.1 million

USPTO issues Notice of Allowance to Sanovas’ nested balloon catheter

Diffusion Pharmaceuticals completes trans sodium crocetinate Phase I trial on glioblastoma

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Bevacizumab ruled out for stage III colorectal cancer

Biomolecular imaging: an interview with Professor Roger Reddel

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in